Ansun Biopharma, Inc.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2003-01-01
- Employees
- 11
- Market Cap
- -
DAS181 for STOP COVID-19
- First Posted Date
- 2020-04-21
- Last Posted Date
- 2020-08-11
- Lead Sponsor
- Ansun Biopharma, Inc.
- Registration Number
- NCT04354389
- Locations
- 🇮🇹
A.O.U Policlinico Di Modena, Modena, Italy
🇮🇹Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milano, Italy
DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19)
- Conditions
- Influenza InfectionSAD-RV Infection and COVID-19
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-03-06
- Last Posted Date
- 2020-07-09
- Lead Sponsor
- Ansun Biopharma, Inc.
- Target Recruit Count
- 280
- Registration Number
- NCT04298060
- Locations
- 🇨🇳
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
- Conditions
- Lower Respiratory Tract InfectionParainfluenzaImmunocompromisedCOVID-19
- Interventions
- First Posted Date
- 2019-01-18
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Ansun Biopharma, Inc.
- Target Recruit Count
- 274
- Registration Number
- NCT03808922
- Locations
- 🇺🇸
MD Anderson, Houston, Texas, United States
🇺🇸Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, Florida, United States
🇺🇸Houston Methodist Hospital, Houston, Texas, United States
An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection
- Conditions
- Parainfluenza
- Interventions
- Drug: DAS181-F02 Dry Powder in BulkDrug: DAS181-F02 Nebulized Formulation Inhaled Dose
- First Posted Date
- 2013-08-19
- Last Posted Date
- 2017-07-19
- Lead Sponsor
- Ansun Biopharma, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT01924793
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Phase 2B Study on Safety and Therapeutic Efficacy of DAS181 in Adult Subjects With Naturally Acquired Influenza
- Conditions
- Influenza
- Interventions
- Drug: DAS181-F04 formulationDrug: PlaceboDrug: DAS181-F02 formulation
- First Posted Date
- 2012-12-04
- Last Posted Date
- 2019-07-08
- Lead Sponsor
- Ansun Biopharma, Inc.
- Target Recruit Count
- 423
- Registration Number
- NCT01740063
- Locations
- 🇺🇸
Nexbio, San Diego, California, United States
A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen
- Conditions
- Parainfluenza
- Interventions
- Drug: DAS181 dry powder, formulation F02
- First Posted Date
- 2012-07-19
- Last Posted Date
- 2017-09-25
- Lead Sponsor
- Ansun Biopharma, Inc.
- Target Recruit Count
- 111
- Registration Number
- NCT01644877
- Locations
- 🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Lurie Children's Hospital, Chicago, Illinois, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
A Safety Trial of DAS181 (Fludase®) in Adult Subjects With Well-Controlled Asthma or Bronchiectasis
- Conditions
- AsthmaBronchiectasis
- Interventions
- Drug: DAS181 dry powder, formulation F02Drug: Respitose ML006 (DMV-Fonterra)
- First Posted Date
- 2010-04-29
- Last Posted Date
- 2019-03-27
- Lead Sponsor
- Ansun Biopharma, Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT01113034
- Locations
- 🇺🇸
NIH Clinical Center, Bethesda, Maryland, United States
Randomized, Double-blind, Placebo Controlled Phase II Study to Examine the Effects of DAS181 in Healthy Adult Subjects With Laboratory Confirmed Influenza
- Conditions
- Influenza
- Interventions
- Drug: DAS181 dry powder, formulation F02Drug: Respitose ML006 (DMV-Fonterra)
- First Posted Date
- 2009-12-22
- Last Posted Date
- 2014-04-08
- Lead Sponsor
- Ansun Biopharma, Inc.
- Target Recruit Count
- 264
- Registration Number
- NCT01037205
DAS181 Single Dose Escalation Study in Healthy Adults
- First Posted Date
- 2009-04-06
- Last Posted Date
- 2019-08-02
- Lead Sponsor
- Ansun Biopharma, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT00876161
- Locations
- 🇺🇸
Quintiles Phase One Services, Overland Park, Kansas, United States
Single Dose Escalating Study of DAS181 in Adults
- First Posted Date
- 2007-09-11
- Last Posted Date
- 2009-01-08
- Lead Sponsor
- Ansun Biopharma, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT00527865
- Locations
- 🇺🇸
Comprehensive Phase One, Miramar, Florida, United States